CD8A and neoplasm: Such vaccines are considered a promising therapeutic approach for HPV16-positive cancer patients, as highlighted by the study of Salomon et al. [128] and a previous study by Grunwitz et al. who also showed that HPV16 E7 RNA-LPX vaccine effectively primes HPV16-specific CD8+ T cells, leading to tumor remission in mice and enhanced tumor immunity [129].